CJC-1295 No DAC

CJC-1295 No DAC

CJC-1295 No DAC (also recognized in laboratory literature as Mod GRF 1-29 or Modified GRF 1-29) is a synthetic 29-amino acid peptide analogue of endogenous growth hormone-releasing hormone (GHRH). By functioning as an agonist—a ligand designed to bind to and activate a target receptor—CJC-1295 No DAC selectively targets the GHRH receptor (GHRHR) to stimulate downstream cell signaling cascades.

This specific compound does not feature the C-terminal Drug Affinity Complex (DAC) modification. Because it lacks this albumin-binding moiety, the peptide exhibits transient, short-acting receptor kinetics. This makes it an ideal tool for researchers aiming to model natural, pulsatile growth hormone signaling rather than the prolonged, continuous receptor activation characteristic of DAC-conjugated variants.

Structural Elements to Observe: In the peptide structure above, note the precise sequence of the 29-amino-acid chain. The tetrasubstituted modification replaces four native amino acids in the original GHRH(1-29) backbone (specifically D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27). These modifications sterically shield the peptide from rapid enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4), vastly extending its stability in vitro without requiring a bulky, half-life-extending DAC group.

Technical Specifications

Research Applications & Mechanism of Interest

The primary focus of CJC-1295 No DAC in laboratory models is its capacity to activate the GHRH receptor with enhanced chemical stability. Because native GHRH is degraded by blood enzymes within minutes, this modified peptide provides a far more resilient baseline for in vitro assays.

Primary areas of investigative research include:

• GHRH Receptor Binding & Signal Transduction: Analyzing how the peptide interacts with the GHRH receptor on cultured anterior pituitary cells, triggering intracellular cyclic adenosine monophosphate (cAMP) accumulation and calcium-dependent signaling pathways.

• Pulsatile vs. Continuous Signaling Dynamics: Using the non-conjugated “No DAC” version to study short-term, episodic receptor activation. This helps map the desensitization thresholds of GHRHR compared to continuous stimulation profiles.

• Enzymatic Resistance & Structure-Activity Relationships (SAR): Studying how the tetrasubstituted amino acid mutations protect the structure from rapid aminopeptidase degradation, specifically investigating the cleavage-resistant properties of the D-alanine at position 2.

• Synergistic Co-Stimulation Assays: Utilizing the compound alongside growth hormone secretagogue receptor (GHSR) agonists (such as Ipamorelin or GHRP-2) to explore parallel, synergistic signaling pathways within complex cellular models.

Storage & Handling Guidelines

To preserve the delicate peptide bonds and prevent premature degradation or hydrolysis during analytical workflows:

• Long-Term Preservation: Store the dry, lyophilized powder in a deeply frozen environment maintained at -20°C or below.

• Short-Term Reconstitution Stability: Once reconstituted in sterile, molecular-grade water or compatible laboratory buffers, keep the solution continuously refrigerated at 2–8°C. Use within 21 days to prevent loss of activity.

• Atmospheric Safeguards: Peptides are sensitive to moisture. Keep the vial tightly sealed inside a desiccated container to protect it from ambient humidity and condensation.

• Physical Integrity: Avoid repeated freeze-thaw cycles of prepared liquid assays, and shield the compound from direct sunlight and ultraviolet (UV) light using opaque or amber vials.

Research Use Only Disclaimer: This product is supplied and sold strictly as a Research Use Only (RUO) laboratory reagent. It is not an FDA-approved drug, medication, dietary supplement, or therapeutic agent, and is strictly prohibited for human or veterinary use. Kimera Chems provides these high-purity peptide reference standards exclusively to accredited institutional laboratories, research academies, and qualified professional investigators for controlled in vitro and preclinical evaluation.

Frequently Asked Research Questions

What is the difference between CJC-1295 No DAC and Mod GRF 1-29?

They are synonyms for the exact same chemical structure. The name “CJC-1295 No DAC” was popularized in the research chemical industry to distinguish this free, tetrasubstituted peptide from the version conjugated to a Drug Affinity Complex (DAC). In pure academic and scientific literature, it is more commonly referred to as Mod GRF 1-29 or Modified GRF (1-29).

How do the specific amino acid substitutions protect the peptide from degradation?

In native GHRH, the enzyme DPP-4 rapidly cleaves the peptide bond between the second (alanine) and third (aspartic acid) amino acids. By replacing the native L-alanine at position 2 with a synthetic D-alanine, CJC-1295 No DAC changes the steric geometry of the backbone. This makes it uncleavable by DPP-4, significantly extending its survival time in experimental assays.

Scientific References

1. Ling, N., Baird, A., Wehrenberg, W. B., Ueno, N., Munegumi, T., & Guillemin, R. (1984). “Structure-activity relationships of growth hormone-releasing factor.” Biochemical and Biophysical Research Communications, 123(2), 854-861. DOI: 10.1016/0006-291X(84)91448-4.

2. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Cleland, G. R. (2006). “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy subjects.” The Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. DOI: 10.1210/jc.2005-1536.

3. Campbell, R. M., Stricker, P., Miller, R., et al. (1994). “In vitro and in vivo characterization of highly potent, enzymatic-cleavage-resistant growth hormone-releasing factor analogues.” Journal of Peptide Research, 44(2), 163-171. DOI: 10.1111/j.1399-3011.1994.tb00508.x.